By Fineline Cube 
Shenzhen-based QuantumPharm Inc. (HKG: 2228), also known as Xtalpi Inc., announced the completion of a Pre-Seed investment in US-headquartered Foundry BioSciences Inc. The round totaling tens of millions of renminbi was led by XtalPi, with participation from Taihill Venture, Yael Capital, and other institutional investors.
Investment Details
The proceeds from the investment will primarily support platform technology upgrades, core team expansion, and the industrial translation of multiple R&D projects. This funding aims to further advance the application of AI-driven protein language models in longevity science.
Foundry BioSciences’ Platform
Foundry BioSciences leverages deep learning to develop next-generation protein language models. These models enable protein function prediction, sequence optimization, and end-to-end biomolecule design. The company’s core focus areas include immune modulation, metabolic health, neuroprotection, and tissue regeneration. It is building an integrated digital infrastructure—from sequence discovery to efficacy validation—to accelerate the design of anti-aging target proteins and streamline product iteration.
Collaboration and Future Plans
Post-investment, Foundry BioSciences will collaborate closely with XtalPi. The partnership combines Foundry Bio’s AI algorithms with XtalPi’s high-throughput synthesis and automated experimentation capabilities to establish a unified R&D platform. This platform will span functional ingredient screening, formulation development, consumer product innovation, and novel therapy discovery. The collaboration aims to shorten the lab-to-market timeline through an “AI-driven design + automated validation” approach, delivering breakthrough innovations to the longevity industry.-Fineline Info & Tech